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AbsTrACT
Objective implantable cardioverter defibrillators can 
treat life-threatening arrhythmias, but may negatively 
influence the last phase of life if not deactivated. 
advance care planning conversations can prepare 
patients for future decision-making about implantable 
cardioverter defibrillator deactivation. This study aimed 
at gaining insight in the experiences of patients with 
advance care planning conversations about implantable 
cardioverter defibrillator deactivation.
Methods in this qualitative study, we held five focus 
groups with 41 patients in total. Focus groups were 
audio-recorded and transcribed. Transcripts were 
analysed thematically, using the constant comparative 
method, whereby themes emerging from the data are 
compared with previously emerged themes.
results Most patients could imagine deciding to have 
their implantable cardioverter defibrillator deactivated, 
for instance because the benefits of an active device no 
longer outweigh the harm of unwanted shocks, when 
having another life-limiting illness, or when relatives 
would think this would be in their best interest. some 
patients expressed a need for advance care planning 
conversations with a healthcare professional about 
deactivation, but few had had these. Others did not, 
saying they solely focused on living. some patients were 
hesitant to record their preferences about deactivation 
in advance care directives, because they were unsure 
whether their current preferences would reflect future 
preferences.
Conclusions although patients expressed a need for 
more information, advance care planning conversations 
about implantable cardioverter defibrillator deactivation 
seemed to be uncommon. Deactivation should be more 
frequently addressed by healthcare professionals, tailored 
to the disease stage of the patient and readiness to 
discuss this topic.
InTrOduCTIOn
The implantable cardioverter defibrillator (ICD) 
treats potentially lethal arrhythmias by either 
antitachycardia pacing or delivering an electrical 
shock.1 About half of ICD patients experience 
potentially painful shocks during their life.2 The 
number of ICD patients has grown, as the indication 
for implantation has been extended from secondary 
to primary prevention.3 While the ICD is effective 
in treating arrhythmias, patients eventually die due 
to deterioration of their underlying heart disease or 
another illness.4 An active ICD delivers shocks in 
the last 24 hours of life in up to 33% of patients 
dying non-suddenly.5 Shocks are potentially painful 
and a source of distress and anxiety for patients and 
relatives.5 6 Shocks can be avoided by timely deacti-
vating the shock function of the ICD.7
International expert consensus statements from 
the European Heart Rhythm Association and Heart 
Rhythm Society recommend to timely and repeat-
edly discuss ICD deactivation with the patient and 
relatives.1 8 This is in line with the international 
advance care planning (ACP) consensus statement.9 
ACP enables individuals to define and discuss goals 
and preferences for future medical treatment and 
care, and to record and review these if appropriate.9 
Previous studies have shown that only a minority of 
patients (27% in a study from 2004,10 up to 35% in 
a study from 20182) had discussed ICD deactivation 
with their healthcare professional and had their 
ICD deactivated prior to death.2 11 It is unknown 
why ICD deactivation is infrequently discussed, and 
what patients would want with their device when 
approaching the end-of-life. It is known that many 
patients are confused about the role of the ICD, 
especially in the last stages of life.12 13
Insight into the experiences of ICD patients 
with ACP conversations about ICD deactivation is 
limited. Having more insight into these experiences 
and on how ICD patients reflect on the end-of-
life might help to increase the understanding of 
how patients think, and how they could best be 
approached in having an ACP conversation. There-
fore, we examined ICD patients’ experiences with 
ACP conversations about ICD deactivation in a 
qualitative focus group study.
MeTHOds
study design and sample
We conducted focus groups with ICD patients, 
recruited via the Dutch national ICD recipient 
association (‘STIN’). A call for participants was 
published in their magazine, on their website and 
on social media channels. Patients were eligible 
when they had an active ICD, were older than 40 
years, able to speak and understand Dutch and to 
provide written consent. Patients who were inter-
ested in participating in the study received infor-
mation via email, accompanied by an informed 
consent form. Focus groups were organised in the 
Erasmus University Medical Center Rotterdam, the 
Netherlands. Patients were compensated for their 
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box 1 Interview guide used to facilitate focus groups
 ► Information provision and communication about the ICD at 
the end-of-life:
 – Did you ever had a conversation with your healthcare 
professional about what to do with your ICD when you get 
older or sick? What was discussed?
 – How do you value the quality of this conversation?
 – How would you prefer to get informed about the ICD at 
the end-of-life?
 ► Attitudes towards ICD deactivation
 – Did you ever think about what to do with your ICD when 
you get older or sick?
 – Would you deactivate the device? Why (not)?
 ► Points for improvement
 – Looking back at the conversation you had with your 
healthcare professional, are there things you would like to 
see improved?
ICD, implantable cardioverter defibrillator
Table 1 Characteristics of patients enrolled in the focus groups 
(n=41)
Gender (male) 23 (56%)
Mean age (SD) 64.3 (9.7)
Marital status
  Unmarried 2 (5%)
  Married 30 (73%)
  Divorced 6 (15%)
  Widowed 3 (7%)
Education
  Less than high school 1 (2%)
  High school graduate 10 (24%)
  Some college 8 (20%)
  College graduate 15 (37%)
  University degree 7 (17%)
Indication for ICD (primary prevention) 24 (59%)
Type of ICD
  Single chamber 9 (22%)
  Dual chamber 6 (15%)
  CRT-D 18 (44%)
  S-ICD 1 (2%)
  Unknown 2 (5%)
Mean years implant (SD) 6.4 (4.8)
CRT-D, cardiac resynchronisation therapy-defibrillator; ICD, implantable cardioverter 
defibrillator; S-ICD, subcutaneous-ICD.
time with a gift card of €25, and received reimbursement for 
travel expenses.
Forty-one patients agreed to participate in the study. Five 
focus groups were organised with respectively nine, eight, nine, 
nine and six patients.
data collection
Focus groups discussions were conducted in September 2017, and 
were led by senior researchers with experience in leading focus 
groups (AB-S, AVdH, JR), and supported by two researchers 
(RS or AB-S) who took field notes. Participants completed a 
questionnaire on demographic characteristics prior to the focus 
group. Focus groups were recorded and subsequently tran-
scribed. Patients received a summary of the transcripts after the 
focus groups were conducted.
An interview guide was used to guide the focus groups (box 1). 
This semi-structured guide was developed by the research group, 
based on expert opinion and previously published literature.13 14 
Topics discussed were: (1) information provision and commu-
nication about the ICD at the end-of-life, (2) attitudes towards 
ICD deactivation and (3) suggestions for improvement of infor-
mation provision and communication.
data analysis
Transcript were analysed thematically, using the constant 
comparative method, a data-analytic process whereby each 
interpretation and finding emerging from the data is compared 
with previous findings.15 Transcripts were read by JR and RS and 
meaningful themes were inductively identified and summarised 
in a preliminary coding tree. The coding tree was discussed with 
the coauthors, tested on one of the transcripts, refined and final-
ised. Subsequently, all transcripts were coded by RS, and checked 
by JR. The two researchers met frequently to discuss the coded 
transcripts, and to discuss and resolve minor disagreements.
Patient and public involvement
A patient advisory group met frequently for the duration of the 
study and provided feedback on informational materials and 
interview guides. At the end of the study, they commented on 
the findings.
resulTs
Focus groups lasted an average of 97 min (range 89–107). 
Patients were more often male (56%) and had a mean age of 
64 (SD 9.7). A majority had their ICD implanted for primary 
prevention (59%), and 44% had a cardiac resynchronisation 
therapy-defibrillator implanted, on average 6.4 (SD 4.8) years 
before participation in the study (table 1).
The results are described along the line of the three key 
elements of ACP: (1) reflection on wishes and preferences; (2) 
discussing preferences with healthcare professionals and rela-
tives; (3) recording and reviewing preferences.9 Illustrative 
quotes per key element are presented in table 2.
reflection on wishes and preferences regarding future ICd 
deactivation
Some patients were not aware that ICD deactivation was an 
option, and one patient thought he was not able to die with an 
ICD (Q1 in table 2). Of those who were aware of ICD deac-
tivation, wishes and preferences differed. Most could imagine 
deciding to have their ICD deactivated one day. However, some 
patients indicated they could not imagine ever asking for deacti-
vation. One patient for instance indicated that deactivating the 
ICD could feel like ‘euthanasia’. Euthanasia, defined as ending a 
patient’s life by administering medication by a physician with the 
explicit intention of hastening death, at the explicit request of 
the patient, who suffers unbearably without prospect on relief, is 
legalised in the Netherlands under strict criteria stipulated by the 
Dutch law.16 Some patients were uncertain about in what situa-
tion deactivating their ICD would be appropriate, stating that 
the decision to deactivate is complex and dependent on multiple 
factors (Q2).
Patients often considered the balance between quality and length 
of life when reflecting on possible future ICD deactivation. This 
balance differed between people, but generally patients indicated 
that postponing death—just because it is possible—without taking 
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Table 2 Illustrative quotes regarding ACP
elements of ACP # Quote Quote
1) Reflection on wishes and 
preferences regarding future 
ICD deactivation
Q1 “I thought they implanted the ICD so I was not able to die”? Male patient, focus group 5
Q2 “When do I have to do this (deactivate—RS)? If I have problems with my heart? Should I do it if I get some sort of cancer? Or 
suffer from dementia? When to deactivate the ICD, that is a difficult question”. Male patient, focus group 4
Q3 “I have that fear (of shocks—RS) as well, and based on that fear I would say deactivate my ICD as quickly as possible when 
something happens. If I get sick or whatever, done with it”. Male patient, focus group 2
Q4 “Well I have the ICD simply to ensure that it intervenes if(…)a cardiac arrest would occur.(…)and there is no other way (to 
terminate the cardiac arrest—RS) than by getting a shock. So I think I’ll welcome it then”. Male patient, focus group 2
Q5 “There is of course a difference when you are terminal due to cancer(…). Because if you are terminal due to your heart 
disease, then such device is much more important. If you would deactivate then, then you will certainly go (die—RS). And 
with cancer, it can be very different”. Female patient, focus group 5
Q6 “I do not want my wife, children and grandchildren to stand beside my bed, while I am bouncing up and down in my last 
moment. I do not want that(…)so for me, it is clear what I want”. Male patient, focus group 4
2) Discussing preferences Q7 “Then he (the cardiologist—RS) told me(…)we could also deactivate halfway through. Well, I thought that was a wonderful 
thought”. Male patient, focus group 3
Q8 “You come in as a patient, you feel like you are giving your life to such a doctor, because that is what it comes down to(…)
and he does not take sufficient time to explain it properly, such an important issue as the end-of-life. And that always annoys 
me(…)they just do not take the time for it. You are there for ten minutes and that’s it”. Male patient, focus group 4
Q9 “(…)I think the cardiologist should pay more attention to that (the ICD at the end-of-life—RS), they should realize that it is a 
very important topic to us”. Male patients, focus group 4
Q10 “I did not have this conversation about when to turn it off, but I do not miss it at all. Because then I think well, I really am in 
a phase of getting better and cure, so then I think yes, I am not waiting for this (conversation about ICD deactivation—RS) at 
all”. Female patient, focus group 2
Q11 “I have talked about it with my children, but they really do not want to know about it yet”. Female patients, focus group 5
3) Recording and reviewing 
preferences
Q12 “I do think about it (deactivation—RS) every now and then, but to record my preferences, let me just say it, that is going too 
far, because you do not know what it is like when you are at that moment, that you are what you recorded”. Female patient, 
focus group 3
Q13 “I will make an advance care directive, not so much because of own situation, but because of the fact that my father died 
six months ago and he had one. Back then I though well, everyone should have such a document because… well, for me it 
felt good and I will make one myself as well”. Female patient, focus group 2
ACP, advance care planning; ICD, implantable cardioverter defibrillator.
quality of life into account does not make sense. The ICD was 
considered a lifesaving device by many patients, which was also 
apparent in how patients talked about their device. They often 
used words such as ‘angel’, ‘guard dog’ and ‘safety net’. However, 
some patients described a ‘love-hate’ relationship with their device: 
previous shocks had saved them from a sudden death, but were 
painful, often a source of concern, and a personal confrontation 
with being ill and the finiteness of life. The possibility of expe-
riencing unwanted shocks while dying was often brought up as 
an important factor when reflecting on the role of the ICD at the 
end-of-life. One patient described that their fear of receiving shocks 
was greater than the fear of dying (Q3). However, another patient 
indicated to always want arrhythmias to be treated by shocks, even 
if death was imminent (Q4).
Some patients stated that living longer with a compromised 
quality of life was undesirable. Losing independence and 
being diagnosed with a life-limiting illness were among the 
most frequently mentioned factors threatening quality of life. 
However, there was a distinction made in the nature of the 
disease. Advanced cancer or advanced lung disease was brought 
up by several patients as a clear indication to ICD deactivation, 
since an active ICD would potentially mean having to live longer 
with symptoms such as pain and discomfort, but, as one patient 
described, a progression of heart disease could make one hesi-
tant about ICD deactivation (Q5).
Patients indicated that their relatives would play an important 
role in the decision-making about ICD deactivation. Several 
patients indicated that they did not want their relatives to witness 
them while receiving shocks at the end-of-life (Q6). On the other 
hand, some others mentioned that if their relatives would want 
them to continue ICD therapy, they would.
discussing preferences
Although patients used different sources of information, 
including the internet and patient folders from the hospital, the 
preferred mode to receive information on ICD deactivation was 
by having conversations with the healthcare professional. Some 
patients had this conversation, mostly with their general practi-
tioner or cardiologist and on their own initiative. Such conver-
sations gave relief to some patients (Q7). The vast majority of 
patients however, indicated they never had such conversations, 
which was source of discontent among some patients (Q8).
Patients described their cardiologist as very knowledgeable on 
a medical-technological level, but some indicated they felt there 
was not always the opportunity to discuss issues with a strong 
emotional component. Various reasons were suggested for this, 
such as a perceived lack of time or willingness of the cardiologist, 
as well as unawareness of importance of the healthcare profes-
sionals (Q9). These patients envisioned a greater role for other 
healthcare professionals to support the cardiologist in conducting 
these conversations, such as nurses or the general practitioner.
There was debate on the timing of conversations about ICD 
deactivation. Some patients thought it was best to engage early 
in ACP conversations about ICD deactivation, starting before 
implantation. However, others felt that bringing up issues 
related to the end-of-life at this stage might be inappropriate, 
since implantation of the ICD felt like a ‘second chance at life’. 
Therefore, some suggested to start up such ACP conversa-
tions during follow-up visits. However, others disagreed, since 
patients might get worried about why the physician would bring 
up the topic at that particular moment. Other moments were 
also identified to discuss ICD deactivation: when faced with a 
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life-limiting illness, or when a do-not-resuscitate order is being 
discussed.
While most patients had positive attitudes towards discussing the 
end-of-life and ICD deactivation, this was not true for all patients. 
Some described they focused on living and getting better, and that 
they felt no need to think about future ICD deactivation (Q10).
Several patients mentioned that they had discussed possible 
future ICD deactivation with their relatives. Some considered 
such conversations to be more important than conversations 
with healthcare professionals. Most patients had positive expe-
riences with talking with their relatives about ICD deactivation. 
Yet, some patients indicated that their relatives did not want to 
engage in such conversations (Q11).
recording and reviewing preferences
Some patients had their preferences for future medical care 
and treatments recorded in an advance care directive, or were 
planning on doing so. Not everyone was in favour of recording 
their preferences about ICD deactivation in a document, because 
they were not sure what they would want when their disease 
would progress. It was also described that, even if someone has 
well-considered ideas and wishes about what to do in specific 
situations, these ideas could be opposite of how someone acts 
when they are actually in that situation, and that people adapt 
to their current situation (Q12). They said that multiple factors 
influence the decision to deactivate, such as prognosis, age and 
severity of illness. Also, they were doubtful whether their wishes 
would be respected. On the contrary, others were in favour 
of reporting their preferences about ICD deactivation in an 
advance care directive. One patient had an earlier experience 
with a loved one at the end-of-life, and indicated that an advance 
care directive gave some clarity (Q13).
dIsCussIOn
Little research has been conducted on the experiences of ICD 
patients with ACP conversations about ICD deactivation. 
Although international expert consensus statements recom-
mend to timely and frequently discuss ICD deactivation with 
the patient,1 recent studies show these conversations are scarce.2 
Several patients in our study indicated that their healthcare 
providers are capable regarding medical-technological issues, 
but felt there was not always the opportunity to discuss topics 
with an emotional component, such as the end-of-life. This 
was also shown in an American focus group study with nurses, 
where nurses stated that physicians sometimes ‘fail’ in consid-
ering psychosocial, economic and ACP aspects of living with 
an ICD.14 Another American interview study with ICD patients 
showed that patients seemed to deprioritise ACP conversations, 
and overemphasise the life-saving abilities of the ICD.17 In our 
study, we saw that some patients were unaware of the option of 
ICD deactivation. This lack of knowledge in the patient could 
decrease the willingness of ICD patients to engage in ACP and 
discuss deactivation.18 19 A lack of ACP conversations might 
impair the decision-making at the end-of-life, leading to reactive 
decision-making concerning ICD deactivation.14 Several patients 
indicated that it is important to discuss ICD deactivation with 
their relatives. However, involving families could also cause 
conflicts, such as relatives wanting the patient to keep the ICD 
active.14 This could be due to a knowledge deficit in the relatives 
as well, and could be reduced by including them in ACP conver-
sations.14 The concern of family conflicts was not mentioned in 
our focus group discussions, although one patient mentioned to 
keep the ICD on if her family would want so.
There was debate on the timing of discussing ICD deactiva-
tion. Some patients were hesitant to discuss deactivation before 
implantation, although this would make it easier to start conver-
sations when deactivation becomes more directly relevant.19 
Previous research showed that conversations about ICD deac-
tivation often only occurred when indicated during follow-up 
or at the end-of-life.11 20 Postponing the discussion until the 
end-of-life is not recommended, since patients might have too 
little time to reflect on their decision, and the last phase of life 
is hard to identify in patients with heart failure,21 as shown in 
a previous study, in which only 15.7% of included healthcare 
professionals were confident in predicting death, which might 
impair the timing of ACP conversations.22
Previous research showed that ICD patients are more 
reserved than other patient groups towards ACP conversa-
tions, among others because the ICD is often implanted before 
patients perceive themselves as being seriously ill.13 Also, the 
ICD is often advocated as a solely life-saving device.23 Also in 
our study, some patients developed a complex psychological 
relationship with their ICD, viewing it as a ‘trusted friend’ 
and an integral part of their body, which might make it diffi-
cult for patients to talk or even think about deactivating the 
ICD.13 24 In our study, some patients indicated they do not 
want a conversation about ICD deactivation. Although this 
should be respected to some extent, since ACP conversations 
should be tailored to the readiness and the phase of life of the 
patients,9 we do feel that the healthcare professional also has 
an informative role, in which all benefits, harms and future 
perspectives of a treatment should be discussed. Also, patients 
should have the opportunity to elicit general treatment prefer-
ences and goals of care in addition to their deactivation pref-
erences, since these might play a role in their later decisions 
about ICD deactivation.25
Possibly helpful for patients might be to record their wishes 
and preferences in an advance care directive. In our study, only 
few patients did so. This was also apparent in other studies that 
showed that patients do often have preferences recorded on for 
instance feeding tubes or respirators, but are hesitant to report 
preferences on ICD deactivation.26 27 Possible explanations for 
this might be that preferences are subject to change, and patients 
are not certain whether their current wishes would represent 
their wishes at the end-of-life. However, recording preferences 
might help patients to actively think about their preferences, and 
could reduce ethical dilemmas or moral distress in relatives or 
healthcare professionals.28 Also, if patients are informed that the 
advance care directive is a ‘living’ document, which can always 
be adjusted, they might be less hesitant to record their wishes.
This is one of the few studies exploring the experiences of ICD 
patients with ACP conversations in depth. A strength is its large 
number of participants29 recruited in multiple centres. Yet, some 
limitations have to be addressed. Participants were recruited via 
the Dutch ICD patient association. It is possible that only people 
responded with special interest in the topic or with negative expe-
riences, and that ACP conversations occur more often in practice. 
Also, it should be noted that most patients in the focus groups 
were in general good health, and not at the end of their lives, 
which might influence their wishes and preferences. Our study 
was conducted in the Netherlands, where there is ample attention 
in the public and medical professional domain to support ACP. 
More generally speaking, it is a country with a rather open debate 
about end-of-life decision-making, also showing from the issue of 
euthanasia that was mentioned in one of the focus groups. This 
means that our findings need replication in other countries and 
cultures.
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Key messages
What is already known on this subject?
 ► Implantable cardioverter defibrillators (ICD) shocks at the 
end-of-life can be painful and a source of distress for patients 
and relatives.
 ► Advance care planning (ACP) conversations about the ICD 
can help patients to make a well-informed decision about 
future ICD deactivation, although research shows that these 
conversations do not occur frequently.
What might this study add?
 ► Several patients could imagine asking for ICD deactivation.
 ► In formulating their preferences and wishes, patients often 
take the balance between quality and length of life, and 
family preferences in consideration.
 ► While ACP conversations about ICD deactivation with 
healthcare professionals are scarce, several patients indicate 
they would want to engage in such discussions. Others say 
not to want this conversation, indicating that they focus on 
living and getting better.
 ► Some patients are reluctant to record their preferences about 
ICD deactivation in an advance care directive.
 ► Patients indicate that their preferences are dependent on the 
situation, and they are unsure whether current preferences 
would reflect future preferences.
How might this impact on clinical practice?
 ► Although many patients want to be informed about ICD 
deactivation, there is no one-size-fits-all approach for ACP, 
since there is variability in how and when patients want to be 
informed, and in their attitudes towards deactivation of the 
ICD.
 ► Healthcare professionals should address the role of the ICD in 
the last phase of life more often, tailored to the readiness of 
the patients to engage in these conversations and the phase 
of life the patient finds himself/herself in.
 ► The balance between quality and quantity of life should more 
often be discussed with the patient in clinical practice.
Implications
This study and previous studies showed a variability in how and 
when patients want to be informed and in their attitudes towards 
deactivation. In line with the international ACP consensus state-
ment,9 we recommend healthcare professionals to explore the 
patient’s readiness to talk about end-of-life and ICD deactivation, 
so that information can be tailored to the needs of the patient. 
Specific time points to explore this are before implantation, at 
battery replacement, when health deteriorates or when a patient is 
referred to palliative care.1 Such conversations about ICD deacti-
vation could be incorporated in more general conversations about 
goals of care, values and preferences, so that a clear understanding 
of the patient’s wishes could be established. We recommend to 
involve relatives in these conversations as well,9 as also indicated 
by the patients in our study.
COnClusIOn
Many patients reflected on the role of their ICD at the end-of-
life and report a need to be better informed about this topic. 
However, ACP conversations with the healthcare professional 
about treatment preferences and ICD deactivation seemed to be 
uncommon. Preferences about ICD deactivation were personal 
and dependent on the situation. Therefore, caution is advised 
in using one-size-fits-all approaches in informing the patient 
about deactivation. Some patients were hesitant to record their 
preferences in an advance care directive, since they were unsure 
whether their current preferences would reflect their future 
preferences.
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